×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen at ASCO 2014

Results from studies involving Amgen's oncology portfolio will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30-June 3.

Abstracts are available on the ASCO website at http://am.asco.org/abstracts and updated data will be presented at the meeting.

If you are at ASCO, stop by Amgen's booth #19042 to learn more about Amgen Oncology.

Follow Amgen on Twitter at http://twitter.com/amgen to receive news updates during ASCO.


Jun 2, 2014 News Release: Amgen Presents New Data on Talimogene Laherparepvec as Single Agent and Combination Therapy in Metastatic Melanoma at ASCO
May 31, 2014 News Release: Amgen Highlights Phase 2 Results Of Vectibix® (panitumumab) Versus bevacizumab in Combination with FOLFOX in Patients with Wild-Type RAS (KRAS and NRAS) Metastatic Colorectal Cancer
May 29, 2014 News Release: Amgen To Host Post-American Society of Clinical Oncology (ASCO) Summary Webcast
May 27, 2014 News Release: Amgen and Onyx Data at ASCO 2014 Highlight Onology Pipeline and Portfolio